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evidence on QoL and long-term survival for prostate cancer patients, including
those with castration-resistant prostate cancer (CRPC). The HTAs recommend ran-
domized clinical trials with sufficient follow-up to measure benefits in terms of
overall survival. The trials should include QoL measurements to establish trade-
offs between potential adverse events and benefits of treatment. CONCLUSIONS:A
lack of evidence on QoL for prostate cancer patients is largely responsible for an
absence of specific recommendations from HTAs on QoL measures for prostate
cancer. This has created uncertainty regarding HTA agencies’ preferred QoL mea-
sures. Several current randomized clinical trials for CRPCwill advance significantly
the QoL evidence pool for prostate cancer.
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OBJECTIVES: Understand what fatigue and pain-specific PRO instruments are be-
ing used in the most recent clinical trials for recently approved prostate cancer
drugs.METHODS:We searched the ClinicalTrials.gov database. Searcheswere lim-
ited to drugs recently approved by the FDA and EMA (cabazitaxel, docetaxel, de-
garelix, histrelin, bicalutamide, leuprolide, leuprorelin, triptorelin), but not to any
specific prostate cancer stage. The search terms used were “quality of life OR QOL
OR patient reported outcome” (outcome measure) and “prostate cancer” (for con-
dition). Phase I trials were not considered. We supplemented the search with re-
views of EMA or CMDh drug labels for PRO information. The search was validated
with a Medline search using the above limitations and search terms, limited to
articles published since 1 January 1999.RESULTS: 67 clinical trialswith PROs or QoL
were identified, 33 docetaxel, 14 bicalutamide, 13 leuprolide/leuprorelin, 5 degare-
lix, 2 triptorelin and 1 cabazitaxel. The MOTIF trial, to determine the efficacy of
modafinil in alleviating fatigue in PC patients undergoing docetaxel-based chemo-
therapy, was the only trial to assess fatigue. FACIT-F and SOMA were the PRO
instruments used. Two docetaxel trials and the cabazitaxel trials were the only
ones to have used a pain-specific PRO, the PPI item from the McGill Pain Question-
naire, to measure this symptom. CONCLUSIONS: Despite the ubiquity of fatigue as
a side effect of both hormonal therapy and chemotherapy for prostate cancer, only
one trial assessed this symptom with a dedicated PRO instrument. Although pain
can be one of themost debilitating symptoms associatedwith prostate cancer, only
three trials used a dedicated PRO instrument to assess this symptom. It is unclear
why more PC trials do not use fatigue and pain-specific PRO instruments.
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OBJECTIVES: To prevent cancer recurrence, each year over 100,000 US women
begin a 5-year course of aromatase inhibitors (AIs) for early-stage breast cancer.
AI-related joint pain (arthralgia) may interfere with patients’ well-being in several
domains. There is no arthralgia measurement tool validated in this population
specifically, and more information is needed about the impact of arthralgia on
patient-reported outcomes (PROs) in these patients. We sought to assess relation-
ships of arthralgia with PROs over the 1st 12 weeks of AI therapy.METHODS: Post-
menopausal female oncology outpatients with early stage breast cancer (N52,
pilot sample of the Breast Cancer Adjuvant Therapy cohort) completed paper sur-
veys prior to AI initiation, and every 2 weeks thereafter for 12 weeks. Pain was
measured in 16 joint locations using a 0-10 numeric rating scale. Baseline covari-
ates included age, comorbidities, existingmajor depressive disorder (PHQ-2), social
support (DUFSS), performance status (ECOG), and menopausal symptoms (FACT-
ES). Time-varying PROs examined included physical function, sleep disturbance,
pain interference, and emotional distress (depression), all of whichweremeasured
using PROMIS static short forms. We used mixed models to analyze arthralgia and
PROs. RESULTS: Mean age was 62 years (SD10). The majority of women had
active performance status (n46) and no major depression (n47) at baseline.
Median worst pain in any joint prior to AI initiation was 1 out of 10 (interquartile
range0-5). Adjusting for baseline covariates, greater arthralgia was associated
with worse physical function (0.09[0.13, 0.04]), greater pain interference
(0.15[0.09,0.20]), and greater emotional distress (0.06[0.01,0.11]) but not
with sleep disturbance (0.01[0.03,0.004]). CONCLUSIONS: These prelimi-
nary findings will be used to develop and validate the Patient-Reported Arthralgia
Inventory, toward improving arthralgia measurement. Our findings contribute to
understanding how arthralgia relates to PROs over the 1st 12 weeks of AI therapy.
Targeted AI adherence interventions will rely on comprehensive longitudinal PRO
information.
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OBJECTIVES: The purposes of this study were to investigate redistribution proper-
ties of EQ-5D-5L and to compare the validity and reliability of each EQ-5D version
for Korean cancer patients. METHODS: Patients visiting one ambulatory cancer
center self-administered the two EQ-5D versions and EORTC QLQ-C30 question-
naire. Redistribution properties are examined between EQ-5D-5L and EQ-5D-3L.
Convergent validity of these two versions was evaluated by comparing EQ-VAS,
ECOG performance status and EORTC QLQ C30 subscales. Discriminant ability was
evaluated based on Shannon index and ceiling effect and test-retest reliability was
evaluated using kappa statistics and intraclass correlation coefficient. RESULTS:
Inconsistent rate was 3.5% between two versions. In convergent validity, EQ-5D-5L
demonstrated similar or higher correlations with EQ-VAS, ECOG performance sta-
tus and EORTC QLQ-C30 compared with EQ-5D-3L. Absolute informativity in EQ-
5D-5L was improved but relative informative is similar to the EQ-5D-3L. Ceiling
effect was decreased from 16.8% in the 3L version to 9.7% in the 5L version. Agree-
ments by Kappa were fair to good in 4 dimensions except usual activities in both
EQ-5D instruments. Intraclass correlation coefficient of EQ-5D-5Lindex was 0.77.
CONCLUSIONS: The EQ-5D-5L version appear a valid and reliable quality of life
instrument in cancer patients. EQ-5D-5L enhanced descriptive richness and dimin-
ished ceiling effect compared with EQ-5D-3L.
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OBJECTIVES: Attachment style, or ability to be self-reliant and trust others, cate-
gorized as secure, preoccupied, dismissing or fearful, is related to health outcomes.
Individuals successfully seeking social support can better cope with negative
events. The attachment style of gay menmay affect their ability to be public about
their sexual orientation and seek support, which could affect their health-related
quality of life (HRQOL). We assessed variation in the attachment style of gay men
with prostate cancer and its relationship with HRQOL. METHODS: Participants
(N91) were from a convenience sample of gaymenwith localized prostate cancer.
HRQOL was measured using the Short Form-36 (SF-36) (v1.0) and the Expanded
Prostate Cancer Index Composite (EPIC); the attachment style was scored using the
Relationship Questionnaire. Differences in attachment style were assessed using
ANOVA. Multiple regressionmodels were run to predict the SF-36 physical (PCS) or
mental (MCS) components. RESULTS: Individuals with dismissing attachment
style had lower social network scores and indicated higher bowel symptom bother,
though their bowel function was higher than that of fearful individuals (p0.05).
Dismissing individuals were more comfortable being public about their sexual ori-
entation than preoccupied individuals; had a higher MCS, but did not differ on PCS
than fearful individuals. After adjusting for demographics, social support, espe-
cially size of social network, predicted the MCS; while bowel functioning, urinary/
sexual bother, and comfort with being public about their sexual orientation pre-
dicted the PCS on the SF-36 (p0.05). CONCLUSIONS: Social network may vary by
attachment style, affecting psychosocial adjustment. Interventions should use at-
tachment style as amarker for limited social support and poor long-termHRQOL to
identify gay men with prostate cancer needing additional assistance.
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BACKGROUND: Bevacizumab has been used in first line NSCLC in Europe since its
regulatory approval in 2007. Bevacizumab has demonstrated significantly improved
survival in randomized phase III trials. However, no HRQoL outcomes have been re-
ported so far. OBJECTIVES: To investigate the comparative HRQoL of bevacizumab-
based therapy versus non-bevacizumab based therapy in 1st line non-squamous
NSCLC in two European countries. METHODS: Data were drawn from the Adelphi
NSCLC Disease Specific Programme, a large cross-sectional study of consecutively
presenting patients in France and Germany in 2010. Physicians provided retrospec-
tive information regarding disease status and treatment patterns, with matched
patients invited to complete a questionnaire including the EQ-5D and FACT-L in-
struments. Propensity scoring methods were used to match the two comparison
groups on confounding variables including age, performance status and time since
diagnosis. A t-test was used to assess the relationship between current treatment
and quality of life. RESULTS: 363 non-squamous patients receiving first line treat-
ment were analysed, of which 132 were currently receiving bevacizumab-based ther-
apy and 231were currently receiving non-bevacizumab-based therapy. The quality of
life scores using the FACT-L instrument (based on thematched samples)were 77.3 for
bevacizumab patients (95% CI 73.7 to 81.0) compared with 74.1 for non-bevacizumab
patients (95% CI 70.9 to 77.33), p0.19. The EQ-5D scores for Progression-Free Survival
were 0.68 for the bevacizumab group (95%CI 0.63 to 0.74) and 0.66 for the comparative
patients (95% CI 0.62 to 0.71), p0.57. CONCLUSIONS: This real-life pilot study shows
that bevacizumab-based therapy does not have any detrimental effect on HRQoL as
measured by the EQ-5D and the FACT-L.
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